A Sánchez Toranzo// Farmacología. De la molécula al paciente. Farmacología endócrina y del metabolismo. Parte 1 eCollection 2014. Guay DR. Drug treatment of paraphilic and nonparaphilic sexual disorders. 2009 Jan. Clin Ther. 31(1):1-31. Gubelin Harcha W, Barboza Martínez J, Tsai TF, Katsuoka K, Kawashima M, Tsuboi R, Barnes A, Ferron-Brady G, Chetty D. 2014 Mar. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol; 70(3):489-498.e3. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD,Matveev V, Mottet N, van der Kwast TH, Wiegel T, Zattoni F. 2013. Guidelines on Prostate Cancer. European Association of Urology. Hobbs K, Handler L. 2013 Feb. Clinical Inquiry: which treatments help women with reduced libido? J Fam Pract. 62(2):102-3. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15;20(24):6269-76. Levy LL, Jason J. 2013. Female pattern alopecia: current perspectives. Int J Womens Health. 5:541–556. Lethaby A, Duckitt K, Farquhar C. 2013 Jan. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev; 1:CD000400. Lo EN, Beckett LA, Pan CX, Robles D, Suga JM, Sands JM, Lara PN Jr. 2015 Feb. Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients.Prosta te Cancer Prostatic Dis. 10. doi: 10.1038/pcan.2015.2. [Epub ahead of print. Lorenzo P, Moreno A, Lizasoain I, Leza JC, Moro MA, Portolés A. Velazquez. 2009. Farmacología básica y clínica, España, Panamericana. 18º edición. Hennenberg M, Stief CG, Gratzke C. 2014 Apr. Pharmacology of the lower urinary tract. Indian J Urol. 30(2):181-8. Raja A, Hori S, Armitage JN. 2014 Apr. Hormonal manipulation of lower urinary tract symptoms secondary to benign prostatic obstruction. Indian J Urol. 30(2):189-93. Rang HP, Dale MM, Ritter JM, Flower RJ. 2008. Rang y Dale Farmacología. Versión en español de la sexta edición de la obra en inglés Rang and Dale´s Pharmacology. Elsevier España, S.L. Barcelona. Richard PO, Finelli A. 2014 May. 5-Alpha reductase inhibitors in active surveillance. Curr Opin Urol. 24(3):324-8. Sasa H, Imai K, Suzuki A, Sei K, Makimura N, Furuya K. 2014 May. Comparison of low-dose dienogest with low-dose danazol for long-term treatment of adenomyosis. Obstet Gynecol. 123(1):97S-8S. Shlomo M, Polonsky KS, Reed Larsen P, Henry M. Kronenberg. 2011. Williams textbook of endocrinology, Phyladelphia, Elsevier Sauders, 12ª edición. Sternberg CN, Petrylak DP, Madan RA, Parker C. 2014. Progress in the treatment of advanced 138
GT Holzmann, CM Ungaro, A Sánchez Toranzo // Farmacología de la obesidad prostate cancer. Am Soc Clin Oncol Educ Book. 34:117-31. Tan YH, Lethaby A. 2013 Nov. Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding. Cochrane Database Syst Rev;11:CD010241. doi: 10.1002/14651858. CD010241.pub2. Zhu H, Garcia JA. 2013 Apr. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor. Curr Oncol Rep. 15(2):105-12. EDITORIAL SCIENS 139
